clinical trial · NCT02783040
Interaction of BI 425809 With Midazolam, Warfarin, Omeprazole and Digoxin
Boehringer Ingelheim·phase1·completed·n = 13
HealthyMidazolamWarfarinOmeprazoleDigoxinBI 425809
brief summary
To assess the influence of multiple doses of BI 425809 on single dose pharmacokinetics of midazolam (CYP3A4 probe drug), warfarin (CYP2C9 probe drug), omeprazole (CYP2C19 probe drug) and digoxin (P-gp probe drug)
started
Sep 7, 2015
primary completion
Oct 30, 2015
completion
Oct 30, 2015
last updated
Apr 15, 2026
official title
A Study to Investigate the Effects of Multiple Doses of BI 425809 on the Single Dose Pharmacokinetics of Cytochrome P450 Substrates (Midazolam, Warfarin and Omeprazole) and a P Glycoprotein Substrate (Digoxin) Administered Orally in an Open-label, One-sequence Trial in Healthy Male Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol